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Objective: The clinical and cost effectiveness of Outpatient Parenteral Antimicrobial 
Therapy (OPAT) services are well described. We used a blood culture database as a 
novel approach to case finding and determined its utility in identifying inpatients suitable 
for OPAT.  
Methods and Patients: From December 2012 to November 2013, consecutive adult in-
patients with bacteraemia, and those recruited to OPAT, were prospectively studied. 
Univariate and multivariate logistic regression analysis were used to investigate the 
association between bacteraemic patient characteristics and OPAT recruitment. 
Results: There were 470 bacteraemic and 134 OPAT patients. The blood culture 
database identified 22 (16.4%; CI 10.5, 23.6) additional patients suitable for OPAT, 4.7% 
(95% CI 3.0, 7.0) of the total bacteraemic cohort. 20 (90.9%) of these patients had 
community-acquired infection, equivalent to 20/200 (10.0%; 95% CI 6.2, 15.0) of all 
community-acquired bacteraemic episodes. Bacteraemic patients with UTIs, 11/157 (7.0%; 
95% CI 3.5, 12.2) were most commonly recruited to OPAT and the commonest blood 
culture isolate was E. coli. In the E. coli bacteraemic sub-group, ESBL producers were 
significantly higher in the OPAT group, compared to those not recruited to OPAT, 9/11 
(81.8%) vs 17/192 (8.9%), p<0.001. Among OPAT patients, there were a higher proportion 
of upper UTIs in the bacteraemic group compared to the non-bacteraemic group, 9/22 
(40.9%) vs 26/123 (21.1%), p = 0.046. There were no OPAT deaths within 30 days and no 
significant difference in relapse rates between bacteraemic and non-bacteraemic patients, 
1/22 (4.6%) vs 5/112 (4.5%). In logistic regression analysis, there were no host factors in 
the bacteraemic cohort that predicted recruitment to OPAT. In a subgroup analysis of 
patients with gram-negative bacteraemia, ESBL production was strongly associated with 
OPAT recruitmentin multivariate analysis, OR 5.85 (95%CI 1.94, 17.58), p=0.002.  
Conclusion: A blood culture database proved a useful adjuvant to a clinical referral 
system, particularly for patients with community onset infections and MDR infections. All 
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bacteraemic patients recruited to OPAT received treatment safely and had good clinical 
outcomes. 
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Introduction: 
 
Outpatient parenteral antibiotic treatment (OPAT) enables patients to receive treatment 
with intravenous antibiotics in their home or in an ambulatory care setting rather than in 
hospital. It is widely used in the UK and is associated with admission avoidance, 
decreased length of inpatient stay, cost savings and high levels of patient satisfaction(1-5). 
In carefully selected patients, outcomes are comparable with hospital based treatment(6,7) 
and National guidelines assist with service delivery, good clinical practice and governance. 
OPAT is also part of the UK government’s healthcare strategy of moving services into the 
community so services are likely to continue to expand over the next 5 years(8). 
 
While there is much published literature on the success of OPAT services, there is little on 
methods used to identify patients. Traditionally, patient identification can be passive, 
waiting for a referral, or active, targeting specific specialties (eg. orthopaedics or Acute 
Assessment units).  Often referrals are unsuitable for several reasons. These include 
patients living outside designated postcodes, inability to attend hospital for treatment on a 
daily basis, being elderly with multiple co-morbidities that necessitate prolonged hospital 
stay, difficulty with vascular access and having conditions treatable with oral antibiotics. 
Bacteraemic patients feature in some OPAT populations although it is unclear what site of 
infection caused these bacteraemias and how these patients were recruited(7,9-11). Overall, 
there is little in the literature on the value of Microbiological results in patient identification 
with the emphasis on clinical and risk assessment and safe delivery of treatment(7,12). We 
used an existing blood culture database as a novel approach for recruitment, and 
determined its utility in identifying adult inpatients suitable for OPAT. 
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Patients and Methods: 
 
Study Setting 
This study was undertaken at the Royal London Hospital (RLH), Barts Health NHS Trust. 
The RLH serves a diverse population of about 250 000 patients in Tower Hamlets, East 
London and is a regional referral centre for the North East London sector. In addition to 
accident and emergency, general medicine, surgery, paediatric and maternity services, the 
RLH has 60 high-dependency and critical care beds (including neurosurgical, renal, and 
obstetric and gynaecological beds), specialist wards for renal transplant and 
haemodialysis patients, and a high-level intensive care unit (ICU). 
 
Study Population  
From December 2012 to November 2013, consecutive bacteraemic in-patients and 
patients recruited to OPAT were prospectively studied. Patients aged < 16 years were 
excluded. 
 
Bacteraemia cohort and definitions 
In bacteraemic adult patients, age, gender, inpatient specialty, site of infection, organism, 
susceptibility profile and mortality related outcomes were recorded. Bacteraemia was 
considered significant if a blood culture was isolated from a patient with a compatible 
clinical syndrome that was unlikely to be a skin or environmental contaminant. This was 
based upon the patient’s history, examination, response to anti-microbial therapy and 
bacterial isolates from other body sites(13). Specialties at the time of bacteraemia were 
categorised as medicine, surgery (including orthopaedics), critical care and obstetrics and 
gynaecology. For hospital-acquired or device related bacteraemia, the Centres for Disease 
Control and Prevention definitions were used to define the sites of infection(14) and for 
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community-onset bacteraemia, sites were defined following clinical, microbiological and 
radiological assessment. Bacteraemia in patients with an unknown source were classified 
as undefined.  
 
Microbiology data 
Blood cultures were analysed using an automated system BacT/ALERT3D (bioMerieux, 
Mary l’Etoile, France). Isolates were identified using either the VITEK MS system 
(bioMerieux, Mary l’Etoile, France, database v2.0) or Bruker Biotyper (Bruker Daltonic, 
Leipzig, Germany, software version 3.0) MALDI-TOF MS systems according to the 
manufacturer’s instructions and the laboratory standard operating procedures. 
Susceptibility testing was performed on the Microscan walkAway system (Siemans 
Healthcare Diagnostics, Deerfield, IL, US). 
 
OPAT cohort, data collection and ascertainment 
Over the same period age, gender, site of infection, medical specialty, presence of 
bacteraemia, duration of treatment and outcomes were recorded for all patients recruited 
to OPAT. Where possible, patients were treated with once daily intravenous antibiotics. 
Patients under 16 years of age were excluded. Patients were recruited by referrals from 
inpatient teams or GPs or actively sought by attendance at Acute Assessment Unit board 
rounds or attendance at multi-disciplinary team (MDT) meetings (eg. Orthopaedics). 
Patients received treatment in their homes or via a fast response nursing team. A blood 
culture database was used to identify additional patients.   
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Statistical analysis 
We analyzed the characteristics of bacteraemic patients (age, gender, place of acquisition, 
inpatient specialty, site of infection and mortality), comparing those who received and did 
not receive OPAT.  For patients recruited to OPAT, we compared patient characteristics 
and duration of intravenous (IV) treatment for bacteraemic and non-bacteraemic patients. 
We also describe bacteraemic isolates from patients who received OPAT and compared 
these to patients who did not receive OPAT. 
Quantitative data are presented as numbers and percentages. Associations between two 
categorical variables were tested using the Pearson Chi-Squared test and continuous 
variables using t-tests.  As patients may present with more than one bacteraemic episode, 
we used number of patients as a denominator to calculate percentages for patient 
characteristics and number of bacteraemic episodes as the denominator for infection 
characteristics.  
Univariate and multivariate logistic regression analysis were used to examine the 
association between age, gender, inpatient specialty and site of infection, and recruitment 
to OPAT in bacteraemic patients. As all bacteraemic episodes in OPAT patients were 
community-onset, we could not adjust for place of acquisition because there were no 
OPAT patients with hospital-acquired bacteraemia. In a subgroup analysis of patients with 
gram-negative bacteraemia, we also examined the association between E.coli infection 
and extended-spectrum beta-lactamases (ESBL) production and recruitment to OPAT. 
Generalised estimating equations (GEE) were used to account for dependency between 
multiple bacteraemic episodes for patients in the univariate and multivariate analysis. Data 
were analysed using Stata SE (Version 13.1). 
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Clinical governance  
The clinical governance audit committee of Barts Health NHS Trust approved the study. 
Ethical approval was not required. 
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Results: 
Over the 12 month period, the number of in-patients with bacteraemia and patients 
recruited to OPAT are illustrated in figure 1.  
   
Bacteraemic patients 
There were 470 patients with bacteraemia yielding 556 positive blood cultures. Patient 
demographic, clinical and mortality data are summarized in table 1. 22 (4.7%; 95% 
confidence interval (CI) 3.0, 7.0) bacteraemic patients were recruited to OPAT. All patients 
recruited had community onset infection (either community-acquired or health-care 
associated). Of these, 20 had community-acquired bacteraemia, equivalent to 20/200 
(10.0%; 95% CI 6.2, 15.0) of all community-acquired bacteraemic episodes.  
 
Compared to surgical patients, significantly more medical patients were recruited to OPAT. 
Outpatient treatment episodes were most commonly for urinary tract infection (UTI), 
11/157 (7.0%; 95% CI 3.5, 12.2), skin and soft tissue infection (SSTI), 3/29 (10.3%; 95% 
CI 2.2, 27.4), GI tract infection (all enteric fevers), 3/8 (37.5%; 95% CI 8.5, 75.5) and biliary 
tract infection, 3/54 (5.6%; CI 95% 1.2, 15.4). There was no significant difference between 
unadjusted 30-day mortality between bacteraemic patients receiving OPAT and those not 
receiving OPAT; 0 vs 24/470 (5.4%; 95% CI 3.3, 7.5). 
 
OPAT patients 
Of the 134 patients who received OPAT, 22 (16.4%; 95% CI 10.5, 23.6) were bacteraemic. 
All these patients were recruited through the blood culture database and were not referred 
from clinical teams. There was one patient with a bacteraemia and a non-bacteraemic 
episode so this information was recorded in both groups. 
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Demographic and clinical data of all OPAT patients are summarized in table 2. Urinary 
tract infection, 11/51 (21.6%; 95% CI 11.3, 35.3) was the commonest cause of 
bacteraemia in OPAT patients. Unadjusted data demonstrated significant differences in 
sites of infection, with more upper UTIs in the bacteraemic group compared to the non-
bacteraemic group, 9/22 (40.9%) vs 26/123 (21.1%), p = 0.046. There were no deaths in 
either bacteraemic or non-bacteraemic patients and no significant difference in relapse 
rates at 30-days; 1/22 (4.6%) vs 5/112 (4.5%).  
 
Total number of days on IV antibiotics received out of hospital was 1198, roughly 
equivalent to the number of bed days saved. The commonest drugs administered were 
either once daily IV ceftriaxone or ertapenem. In bacteraemic and non-bacteraemic 
groups, median (IQR) duration of intravenous treatment was non-significantly different, 7 
(5-8) vs 6 (3-8). 
 
Microbiology 
For all bacteraemic patients, 378 (68.0%) blood culture isolates were Gram negative. The 
commonest organisms were E. coli, and S. aureus (Table 3). More patients with E. coli 
bacteraemia were recruited to OPAT compared to other blood cultures isolates and, 
among these, ESBL production was significantly higher in the OPAT group compared to 
the non-OPAT group, 8/9(88.9%) vs 19/192 (9.9%), p<0.001.  
 
Bacteraemic patient characteristics and recruitment into OPAT 
Univariate and multivaritate logistic regression analysis to investigate the association 
between bacteraemic patient characteristics and those recruited to OPAT is reported in 
table 4. There were no statistically significant associations in univariate or multivariate 
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analysis. In a sub-group analysis of patients with gram-negative bacteraemia, ESBL 
production was strongly associated with OPAT recruitment, OR 5.85 (95%CI 1.94, 17.58), 
p=0.002.
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Discussion: 
 
This is the first paper to examine the utility of a blood culture database to identify patients 
suitable for OPAT. An additional 16.4%, or 22 extra patients, were recruited to OPAT 
through the blood culture database.  Although a useful adjuvant to a clinical referral 
system, more patients were not recruited probably due to the severity of bacteraemic 
infection, as bacteraemic patients often require resuscitation in hospital. Also, many 
patients admitted from the community can be switched to oral alternatives and, in the 
absence of drug resistance, do not require prolonged intravenous therapy. Our data shows 
that patients with community-onset and multidrug resistant (MDR) infections were most 
likely to be recruited to OPAT, and none of these patients were identified through the 
clinical referral system.     
 
The commonest sites of infection in patients recruited to OPAT were UTIs and SSTIs. A 
two year retrospective review of patients treated with OPAT in one Scottish centre found 
the majority of infections were SSTIs, 125 (59%) of 212 episodes(5). All were identified 
clinically and, in our study, we also found that these patients were predominantly recruited 
by clinical assessment rather than blood culture findings. In contrast, the blood culture 
database was particularly useful in identifying patients with MDR UTIs. One paper 
retrospectively reviewed the use of OPAT to facilitate early discharge of patients with UTI 
caused by ESBL producing Enterobacteriaceae. In this small retrospective study, there 
were 11 patients with 25 treatment episodes, although it is unclear whether any of these 
bacteraemic patients were identified through laboratory results. It concluded that OPAT 
administration of ertapenem was effective and decreased costs associated with MDR 
UTIs(15), a finding similar to ours. Our blood culture database was also useful in identifying 
other medical conditions not normally treated with IV antibiotics out of hospital, including 
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enteric fevers, biliary tract infections and central venous catheter associated infections 
where line salvage was being attempted.  
 
There were no deaths in the OPAT group with bacteraemia, despite bacteraemia being a 
marker of severe infection. Many of these patients were recruited after hospital admission 
and then stabilized before discharge on an intravenous antibiotic. In addition to reducing 
length of inpatient stay, our data demonstrates the safety of this approach. Among 
bacteraemic patients recruited to OPAT, all had community onset infections.  Hospital 
acquired infections are generally medical device or procedure related and more commonly 
occur in patients in critical care areas(16), so it is not surprising that the majority of patients 
recruited had community-acquired infection.  
 
There were limitations to this study. Because of our proactive approach, it is possible 
patients were identified before clinical teams had time to refer to OPAT. The numbers of 
bacteraemic patients recruited to OPAT were small and as there were few deaths in the 
‘bacteraemic’ and ‘non-bacteraemic’ groups, a survival analysis was not possible. In 
logistic regression analysis, we were unable to include place of acquisition in the model as 
no patients with hospital-acquired infection were recruited to OPAT. In a larger study, 
where patients with hospital-acquired occurred, we could have tested the association 
between community-onset bacteraemia and OPAT recruitment. The sample size was, 
however, big enough to demonstrate significant differences in unadjusted and adjusted 
data.  
 
In summary, our study demonstrates that a blood culture database provided a useful 
adjuvant to a clinical referral system for OPAT recruitment. The blood culture database 
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was particularly useful for identifying patients with community-onset infections and MDR 
UTIs. Bacteraemic patients received treatment safely and all had good clinical outcomes.        
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Figure 1: In-patients with bacteraemia and patients recruited to OPAT between 
December 2012 and 2013   
470 bacteraemic patients 134 OPAT patients 
448 (95.3%) patients not 
recruited to OPAT  
22 bacteraemic OPAT 
patients  
112 (83.6%) non-bacteraemic 
OPAT patients  
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Table 1: Demographic and clinical data on 470 patients, with 556 associated 
bacteraemic or fungaemic episodes, who did and did not receive OPAT 
 OPAT P-
value1 Yes No 
Patients 22 448  
Infections (Bacteremic / fungaemic episodes) 25 531  
Age2 (years),  
n (%) 
16 – 30  
31 – 50  
51 - 70  
> 70  
2 (9.1)  
7 (31.8) 
8 (36.4) 
5 (22.7) 
38 (8.5) 
99 (22.1) 
156 (34.8) 
155 (34.6) 
0.621 
Gender2, n 
(%) 
Male 
Female 
11 (50.0) 
11 (50.0) 
262 (58.5) 
186 (41.5) 
0.431 
Place of  
Acquisition, 
n (%) 
CA 
HCA 
HA 
Not defined 
20 (90.9) 
2 (9.1) 
0 
0 
188 (35.4) 
198 (37.3) 
143 (26.9) 
2 (0.4) 
<0.001 
Specialty, n 
(%) 
Medicine  
Surgery 
O&G 
22 (88.0) 
2 (8.0) 
1 (4.0) 
430 (81.0) 
101 (19.0) 
0 (0.0) 
<0.001 
Sites of 
Infection, n 
%) 
CVC (uncomplicated) 
           Tunnelled 
           Non-tunelled 
3CVC (complicated / metastatic spread) 
Peripheral cannula 
Urinary tract (catheter associated) 
4Urinary tract (non-catheter associated) 
Biliary tract 
5GI tract  
GU tract 
Liver abscess 
LRT (non-ventilator associated) 
LRT (ventilator associated) 
Skin and soft tissue infection 
6Peripheral joints (native) 
Peripheral joints (prosthetic) 
Meningitis 
Not defined 
 
0 
2 (8.7) 
2 (8.0) 
 
 
11 (44.0) 
3 (12.0) 
3 (12.0) 
 
 
 
 
3 (12.0) 
1 (4.0) 
 
 
 
 
33 (6.2) 
27 (5.1) 
21 (4.1) 
1 (0.2) 
58 (10.9) 
146 (27.5) 
51 (9.6) 
32 (6.0) 
9 (1.7) 
9 (1.7) 
35 (7.0) 
4 (0.8) 
26 (4.9) 
2 (0.4) 
1 (0.2) 
3 (0.6) 
73 (13.8) 
0.129 
Mortality, n 
(%) 
 
Inpatient 
7 day 
30 day 
 
0 
0 
0 
 
22 (4.9) 
12 (2.7) 
24 (5.4) 
 
0.287 
0.437 
0.265 
OPAT: Outpatient parenteral antibiotic treatment O&G: obstetrics and gynecology CVC: central 
venous catheter CO: community-onset HA: hospital-acquired  
1Chi2 test 
2patient specific variables. Age and gender were reported as a percentage of patients  
3Complicated CVC or metastatic infections occurred only in renal haemodialysis patients. This 
included vertebral column, infective endocarditis and pacemaker infection. 
4 2 were complicated lower UTIs, one post prostatic biopsy 
5 Enteric fevers (2 x S. paratyphi and 1 x S. typhi) 
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6 Metastatic complication of fistula site and catheter associated UTIs in renal haemodialysis 
patients. 
One patient had a bacteraemic and non-bacteraemic episode, so this was recorded in both groups.
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Table 2: Demographic and Clinical data on 134 patients who received OPAT (145 
treatment episodes), with bacteraemia and without bacteraemia. 
 Without bacteraemia With bacteraemia p-value1 
Patients 112 22  
Episodes 123 22  
Age2 (years), n (%) 
  16-30  
  31-50  
  51-70  
  > 70  
 
20 (17.9) 
35 (31.3) 
35 (31.3) 
22 (19.6) 
 
2 (9.1) 
7 (31.8) 
8 (36.4) 
5 (22.7) 
0.777 
Gender 2, n (%) 
  Male 
  Female 
 
51 (45.5) 
61 (54.5) 
 
12 (50.0) 
11 (50.0) 
0.701 
Specialty, n (%) 
  Medical 
  Surgical 
  O&G 
 
109 (88.6) 
10 (8.1) 
4 (3.3) 
 
19 (86.4) 
2 (9.1) 
1 (4.6) 
0.941 
Site of infection, n (%) 
  Urinary tract (upper) 
  Urinary tract (lower) 
  Biliary tract 
  Skin and soft tissue 
  Central venous catheter 
  GI tract 
  Infective endocarditis 
  LRT  
  Meninges 
  Orthopaedic infections 
       Vertebral column (VC) 
       Osteomyelitis (non-VC) 
       Peripheral joints 
       Sternal wound 
   Other 
 
26 (21.1) 
14 (11.4) 
0 
57 (46.3) 
0 
2 (1.6) 
0 
1 (0.8) 
2 (1.6) 
6 (4.9) 
2 
0 
3 
1 
415 (12.2) 
 
9 (40.9) 
32 (9.1) 
2 (9.1) 
2 (9.1) 
2 (9.1) 
3 (13.6) 
1 (4.6) 
0 
0 
1 (4.6) 
0 
0 
1 
0 
0 
0.025 
Outcome2 , n (%) 
   Recovered / anticipated   
outcome 
   Relapse 
 
107 (95.5) 
 
5 (4.5) 
 
21 (95.5) 
 
1 (4.6) 
0.987 
Death within 30 days of 
treatment completion, N (%) 
0 0 N/a 
Duration of IV treatment (days) 
Mean (SD) 
Median (max-min) 
 
8.6 (9.5) 
7.0 (0.0 – 64.0) 
 
6.2 (4.0) 
6.0 (0.0 – 14.0) 
0.207 
OPAT: Outpatient parenteral antibiotic treatment O&G: obstetrics and gynecology; SSTI: skin and 
soft tissue infection; GI: Gastrointestinal; LRT: lower respiratory tract; SD: standard deviation 
1Chi2 test for categorical variables, t-test for continuous variables 
2 Patient specific variables so reported as a percentage of patients. One patient is in both columns 
because they had one episode without bacteraemia and one with bacteraemia. 
3 One post prostatic biopsy 
4 Other included liver abscesses, malignant otitis externa, meningitis, leptospirosis, infected 
ovarian cysts, pre-patella bursitis, fistula infection, TB, bronchiectasis and community-acquired 
pneumonia with empyema. 
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Table 3 
Bacteremia isolates on 470 patients, with 556 associated bacteraemic or fungaemic 
episodes, receiving or not receiving OPAT 
 OPAT p-value1 
Yes (N=25) No (N=531) 
E. coli, n (%) 11 (44.0) 192 (36.2) 0.426 
   ESBL +ve 9 19 <0.0013 
   ESBL -ve 2 173 
K. pneumonia, n (%) 2 (8.0) 51 (9.7) 0.812 
   ESBL +ve 0 14 0.3883 
   ESBL -ve 2 37 
P. aeruginosa, n (%) 0 24 (4.5) 0.277 
MSSA, n (%) 2 (8.0) 51 (9.7) 0.789 
MRSA, n (%) 0 3 (0.6) 0.706 
Candida species, n (%) 1 (4.0) 9 (1.7) 0.397 
Other2, n (%) 9 (36.0) 202 (38.0) 0.837 
OPAT: Outpatient parenteral antibiotic treatment; MSSA; methicillin-susceptible Staphylococcus 
aureus; MRSA: methicillin-resistant Staphylococcus aureus; ESBL: extended-spectrum beta-
lactamases  
1Pearsons chi2 test. Tests each bacteraemic isolate verses all other bacteraemic isolate 
2These include 2 S. paratyphi, 1 S. typhi, 1 P. mirabilis, 1 E. aerogenes, 1 Group G streptococcus, 
1 Viridans Streptococcus, 1 Acinetobacter and 1 Candida haemulonii. 
3ESBL +ve verses ESBL –ve for each bacteraemic isolate 
.One patient had a bacteraemic and non-bacteraemic episode, so this was recorded in both 
groups. 
  
  
Table 4: Univariate and multivariate logistic regression analysis for all bacteraemic patients to investigate association between 
patient characteristics and recruitment to OPAT 
(469 patients, 555 bacteraemic patients) 
 Univariate analysis Multivariate analysis 
Odds Ratio (95% CI) p-value1 Odds Ratio (95% CI) p-value1 
Age (years) 16 – 30  
31 – 50  
51 - 70  
> 70  
Reference 
1.18 (0.23, 6.06) 
1.02 (0.21, 4.98) 
0.61 (0.12, 3.28) 
0.733 Reference 
1.12 (0.22, 5.80) 
0.91 (0.18, 4.45) 
0.51 (0.09, 2.79) 
0.633 
Gender Female 
Male 
Reference 
0.79 (0.34, 1.86) 
0.593 Reference 
0.89 (0.37, 2.12) 
0.799 
Speciality Medicine  
Surgery 
Reference 
0.43 (0.10, 1.83) 
0.254 Reference 
0.42 (0.10, 1.78) 
0.237 
Site of infection Urinary tract 
Skin and soft tissue 
Other 
Reference 
1.64 (0.40, 6.77) 
0.67 (0.27, 1.62) 
0.415 Reference 
1.54 (0.36, 6.67) 
0.61 (0.24, 1.52) 
0.349 
1 patient with obstetrics and gynecology speciality was excluded 
Generalised estimating equations were used to adjust for multiple episodes for some patients 
OPAT: Outpatient parenteral antibiotic treatment ; CI: confidence interval 
1Joint wald test 
  
Table 5: Univariate and multivariate logistic regression analysis for gram-negative bacteraemic patients to investigate 
association between blood culture isolate and recruitment to OPAT 
(332 patients, 377 bacteraemic patients) 
 Univariate analysis Multivariate analysis 
Odds Ratio (95% CI) p-value1 Odds Ratio (95% CI) p-value1 
Age (years) 16 – 30  
31 – 50  
51 - 70  
> 70  
Reference 
1.56 (0.17, 14.11) 
1.03 (0.12, 8.94) 
0.47 (0.05, 4.77) 
0.464 Reference 
1.67 (0.17, 16.42) 
0.97 (0.10, 9.12) 
0.53 (0.05, 5.76) 
0.544 
Gender Female 
Male 
Reference 
0.67 (0.24, 1.88) 
0.442 Reference 
0.76 (0.25, 2.25) 
0.614 
Speciality Medicine  
Surgery 
Reference 
0.30 (0.04, 2.28) 
0.242 Reference 
0.28 (0.03, 2.23) 
0.228 
Site of infection Urinary tract 
Skin and soft tissue 
Other 
Reference 
4.69 (0.49, 44.82) 
0.85 (0.29, 2.49) 
0.341 Reference 
5.94 (0.39, 89.49) 
0.73 (0.22, 2.41) 
0.296 
E.coli No 
Yes 
Reference 
1.01 (0.36, 2.83) 
0.987 Reference 
1.21 (0.37, 3.95) 
0.756 
ESBL 
production 
negative 
positive 
Reference 
6.15 (2.13, 17.75) 
0.001 Reference 
5.85 (1.94, 17.62) 
0.002 
1 patient with obstetrics and gynecology speciality was excluded 
Generalised estimating equations were used to adjust for multiple episodes for some patients 
OPAT: Outpatient parenteral antibiotic treatment ; CI: confidence interval; ESBL: extended-spectrum beta-lactamases 
1Joint wald test 
 
 
